Home »

Amunix and PolyPeptide Enter Into Partnership to Produce XTEN(TM) Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics

MOUNTAIN VIEW, CA — (Marketwired) — 10/28/14 — Amunix Operating Inc., and PolyPeptide Laboratories, Inc. (PPL) have entered into a partnership under which Amunix–s proprietary recombinantly derived polypeptides (XTEN) will be chemically conjugated to other peptides. Under the terms of the Agreement, PPL will produce XTENylated peptides for third-party entities to facilitate evaluation of the resulting conjugates as therapeutic compounds. XTEN is Amunix–s proprietary protein-based polymer t

Amunix Signs a Services and Supply Agreement With the University of Nebraska-Lincoln to Produce GMP-Grade XTEN(TM) for Pharmaceutical Therapeutics

MOUNTAIN VIEW, CA — (Marketwired) — 10/27/14 — Amunix Operating Inc., a biotechnology company developing polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules, announced it has entered into a Services and Supply Agreement with the University of Nebraska-Lincoln Biological Process Development Facility to provide kilogram-scale, GMP-Grade XTEN for chemical conjugation. XTEN is Amunix–s proprietary protein-based polymer that mimi

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de